View Older Stories View More Recent Stories

Aug 15, 2023 04:15PM Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
Aug 8, 2023 04:05PM Veracyte Announces Second Quarter 2023 Financial Results
Aug 1, 2023 08:15AM Veracyte (VCYT) Reports Study Showing Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Aug 1, 2023 08:15AM Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Jul 19, 2023 05:00PM Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
Jun 20, 2023 08:31AM New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
Jun 12, 2023 08:31AM Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
May 25, 2023 05:13PM New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
May 24, 2023 09:00AM New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
May 23, 2023 05:00PM Veracyte to Participate in Upcoming Investor Conferences
May 12, 2023 06:15AM Veracyte (VCYT) Announces New Data Showing Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023 06:15AM Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 4, 2023 04:05PM Veracyte Announces First Quarter 2023 Financial Results
May 4, 2023 09:45AM New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 3, 2023 05:44PM New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 2, 2023 04:06PM Veracyte (VCYT) Reports Publication Validating Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
May 2, 2023 04:05PM Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 1, 2023 05:35PM Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
Apr 29, 2023 04:31PM Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
Apr 27, 2023 04:05PM Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
Apr 17, 2023 08:30AM New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
Apr 13, 2023 05:00PM Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
Apr 12, 2023 08:30AM Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Mar 15, 2023 04:15PM Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
Mar 13, 2023 05:51AM Veracyte (VCYT) Statement on Impact of Silicon Valley Bank
Mar 11, 2023 12:11PM Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
Feb 27, 2023 05:00PM Veracyte to Participate in Upcoming Investor Conferences
Feb 22, 2023 04:05PM Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
Feb 15, 2023 08:38AM Veracyte (VCYT) Says Data Published in "The Red Journal" Validate Prognostic Value of Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
Feb 15, 2023 08:36AM Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
Feb 13, 2023 05:23PM New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Feb 6, 2023 05:00PM Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
Feb 1, 2023 04:05PM Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Feb 1, 2023 08:33AM Veracyte (VCYT) Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
Feb 1, 2023 08:32AM Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
Jan 23, 2023 09:00AM Exagen Inc (XGN) Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Jan 23, 2023 09:00AM Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Jan 23, 2023 09:00AM Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Dec 15, 2022 04:05PM Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Nov 2, 2022 04:05PM Veracyte Announces Third Quarter 2022 Financial Results
Nov 1, 2022 05:11PM Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
Oct 27, 2022 05:00PM Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
Oct 25, 2022 08:30AM New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
Oct 24, 2022 08:30AM Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
Oct 18, 2022 04:05PM New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Oct 13, 2022 05:00PM Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
Sep 22, 2022 08:56AM Veracyte (VCYT) Announces New Data Published in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
Sep 22, 2022 08:55AM New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
Sep 13, 2022 08:30AM Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
Sep 12, 2022 05:43AM Veracyte (VCYT) Reports Strong Phase 3 Data of Decipher Prostate Genomic Classifier
View More Recent Stories View Older Stories